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Elevation Myocardial Infarction*
Bruce R. Brodie, MDMen talk of killing time,
while time quietly kills them.
—Dion Boucicault, 19th-century
Irish-American playwright (1)SEE PAGE 778R eperfusion therapy, ﬁrst with ﬁbrinolyticsand now with primary percutaneous coro-nary intervention (PCI), has revolutionized
the management of patients with ST-segment eleva-
tion myocardial infarction (STEMI). Over the past
25 years, short-term mortality in STEMI patients has
fallen from 13% in the control arms of early ﬁbrino-
lytic trials in the 1980s to 2% to 4% in contemporary
trials in patients treated with primary PCI and op-
timal adjunctive therapies.
It was recognized very early that time to treatment is
a crucial metric in determining outcomes with reper-
fusion therapy. Earlyﬁbrinolytic trials andmore recent
primary PCI trials have documented that delays in
reperfusion resulting in prolonged ischemic time
have translated into increased mortality (2,3). Eitel
et al. (4) have graphically shown that myocardial
salvage by magnetic resonance imaging falls off
rapidly with increasing time to treatment with primary
PCI. Much data have been accumulated supporting the
mantra that “time is muscle” and that delays in time to
reperfusion are associated with increased mortality.
Dion Boucicault’s quote describes the passage of time
and the mortality of man, but could just as well
describe the passage of time and mortality from
myocardial infarction—time (not so) quietly kills.*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the LeBauer Cardiovascular Research Foundation, Cone Health
Heart and Vascular Center, Greensboro, North Carolina. Dr. Brodie has
reported that he has no relationships relevant to the contents of this
paper to disclose.Considering the critical importance of ischemic
time as a metric in reperfusion therapy for STEMI
patients, it is ironic and somewhat disturbing that
the measure of ischemic time depends entirely
upon the patient’s subjective determination of
the time of onset of his/her symptoms. Mahmoud
et al. (5) in this issue of JACC: Cardiovascular In-
terventions have presented an observational study
that provides a more objective estimate of the
time of onset of myocardial infarction that could
alter our understanding of the relationship be-
tween ischemic time and outcomes with reperfusion
therapy.The Mahmoud et al. study (5) compares patient-
reported symptom onset time with biological onset
time determined from serial troponin levels in STEMI
patients undergoing primary PCI. The authors calcu-
lated the time of initial troponin elevation by ﬁtting a
regression line to the rising troponin levels after
logarithmic transformation of both time and troponin
levels, and extrapolating backwards to estimate the
time of initial troponin elevation (a troponin value of
0.01 ng/ml). The time of onset of myocardial infarc-
tion was set at 4 h before initial troponin elevation,
on the basis of clinical and pre-clinical studies
relating the time of coronary occlusion to initial
troponin elevation.
The authors found that the time of onset of
myocardial infarction by this method (biological
onset time) was 4.2 h earlier than patient-reported
symptom onset time, and these differences were
more pronounced in elderly patients, patients with
low body mass index, no previous PCI, initial
Thrombolysis In Myocardial Infarction (TIMI) ﬂow
grade >0, and patients at higher risk of mortality.
The validity of this method was supported by the
observation that ischemic time based on biological
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789onset time correlated with 1-year mortality and
infarct size estimated by peak troponin levels,
whereas ischemic time based on reported symptom
onset time did not.
It is somewhat surprising that the differences in
biological onset time and symptom onset time were
so great. This may partly be related to the constant
chosen (4 h) to represent the time from coronary
occlusion to ﬁrst troponin elevation, which is some-
what arbitrary. Determination of this constant is
problematic because animal models evaluating the
time from coronary occlusion to troponin elevation
may not translate directly to the human situation, and
evaluations comparing symptom onset time to ﬁrst
troponin elevation would be using measurements
from a standard we are trying to replace. It is known
that the process of coronary occlusion leading to
STEMI is often a dynamic process with a series of
small plaque ruptures with partial coronary occlu-
sion and distal embolization of platelet aggregates
and thrombus, usually leading up to complete cor-
onary occlusion with ST-segment elevation. Some-
times, these early plaque ruptures may be silent but
lead to troponin release, so it is understandable
that the time of ﬁrst troponin elevation sometimes
occurs before the onset of symptoms, as was shown
in this paper (5).
The investigators point out that patients fre-
quently have problems reporting the onset of symp-
toms, and this may also contribute to the wide
difference between biological onset time and symp-
tom onset time. Elderly patients may have difﬁculty
remembering the time of symptom onset, diabetic
patients frequently have silent ischemia, and women
frequently have atypical symptoms with ischemia.
Patients with TIMI ﬂow grade >0 on initial angiog-
raphy are more likely to have a series of plaque rup-
tures without complete occlusion with stuttering
symptoms or no symptoms, and this may explain the
greater difference between biological onset time and
symptom onset time in this group of patients.
The study has some important limitations. Many
STEMI patients treated with primary PCI were
excluded from the study because there were no data
on patient-reported symptom onset time or because
serial troponin values were not available. Only 602 of
2,646 STEMI patients treated with primary PCI during
the study period were included, and compared with
excluded patients, this was a low-risk group with
hospital and 1-year mortality rates of only 1.8% and
5.7%, respectively. Peak troponin levels were low
(median 3.7 ng/ml), probably because troponin levels
were not routinely collected beyond 6 h, and thiscould potentially affect the assessment of infarct size
and the relationships between ischemic time and
infarct size. Finally, as the authors point out, because
reperfusion with primary PCI can affect troponin
levels because of washout, these data cannot be
applied to STEMI patients who do not receive reper-
fusion therapy or who are treated with ﬁbrinolytic
therapy.
A major limitation of biological onset time, as
determined in this study (5), is that it cannot be used
prospectively, because 2 elevated troponin values are
needed to make the assessment. The method may still
be used in retrospective analyses of clinical trials to
better understand the relationship between ischemic
time and outcomes with various reperfusion strate-
gies and with new adjunctive therapies. Perhaps even
more exciting are the possibilities that new technol-
ogy could allow prospective assessment of biological
onset time. The use of multiple markers of myo-
cardial injury with varied release kinetics measured
at the time of patient presentation could poten-
tially allow an estimate of the time of onset of
myocardial infarction. For example, high-sensitivity
cardiac troponin measurements can be detected
sooner after the onset of symptoms than standard
cardiac troponin measurements, and these could be
used to help stratify the time of onset of myocardial
infarction (6).
If the results of this study are conﬁrmed by larger
trials, and if methodology can be developed to
allow prospective estimates of ischemic time, the
new methodology could potentially impact clinical
practice. Ischemic time is critical early after the
onset of myocardial infarction, and delays to re-
perfusion during this early time period have a major
adverse effect on outcomes, whereas delays later
after the onset of myocardial infarction are less
critical (7). A more objective measure of ischemic
time could alter strategies regarding choice of
reperfusion therapy and systems of care to reduce
ischemic time. Ischemic time may be critical in
determining whether adjunctive therapies with pri-
mary PCI will be effective. Therapies aimed at
reducing infarct size, such as cooling, distal pro-
tection against embolization, and pharmacological
agents, have the potential to be beneﬁcial early
after the onset of myocardial infarction, when
myocardial salvage is possible, but not later. A
better method of assessing ischemic time might
allow targeting patients more likely to beneﬁt from
such therapies.
The Mahmoud et al. study (5) offers a new
method and exciting possibilities for re-assessing the
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790relationship between ischemic time and outcomes
in STEMI patients treated with primary PCI and
adjunctive therapies. New studies with this or similar
methodologies could alter current paradigms and
impact clinical practice. We may see a new time clock
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